Open AccessProgress in the Pathogenesis and Treatment of Heart Failure with Preserved Ejection Fraction
Author(s) -
Xinyu Song,
Zhixiang Zhang
Publication year - 2021
Publication title -
proceedings of anticancer research
Language(s) - English
Resource type - Journals
eISSN - 2208-3553
pISSN - 2208-3545
DOI - 10.26689/par.v5i5.2570
Subject(s) - heart failure , heart failure with preserved ejection fraction , pathogenesis , medicine , ejection fraction , cardiology , diastole , clinical practice , diastolic heart failure , intensive care medicine , blood pressure , physical therapy
Heart failure with preserved ejection fraction (HFpEF) is a special and common clinical heart failure with left ventricular diastolic dysfunction. It has attracted much attention at home and abroad in recent years because of its high heterogeneity and complex pathogenesis. Compared with heart failure with reduced ejection fraction (HFrEF), HFpEF has complex clinical manifestations, many complications, limited clinical treatment, and poor prognosis. In recent years, the research on the pathogenesis and treatment of HFpEF has made certain progress, but there are no specific guidelines for clinical practice. By combing the latest research at home and abroad, the pathogenesis and treatment of HFpEF are systematically reviewed in order to provide a relevant basis for reference its clinical treatment.